X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
index medicus (43) 43
oncology (34) 34
female (31) 31
male (26) 26
middle aged (25) 25
aged (23) 23
cancer (21) 21
adult (18) 18
antineoplastic agents - therapeutic use (14) 14
kidney neoplasms - drug therapy (13) 13
carcinoma, renal cell - drug therapy (12) 12
indoles - therapeutic use (12) 12
metastasis (12) 12
pyrroles - therapeutic use (12) 12
treatment outcome (11) 11
carcinoma (10) 10
chemotherapy (10) 10
interferon-alpha (10) 10
positron-emission tomography (10) 10
tumors (10) 10
urology & nephrology (10) 10
kidney neoplasms - pathology (8) 8
medicine, general & internal (8) 8
positron-emission-tomography (8) 8
sunitinib (8) 8
tyrosine kinase inhibitor (8) 8
abridged index medicus (7) 7
care and treatment (7) 7
docetaxel (7) 7
grasslands (7) 7
patients (7) 7
pet (7) 7
pet imaging (7) 7
positron emission tomography (7) 7
renal-cell carcinoma (7) 7
research (7) 7
therapy (7) 7
urology (7) 7
aged, 80 and over (6) 6
animals (6) 6
antineoplastic agents - pharmacokinetics (6) 6
lung cancer (6) 6
lung cancer, non-small cell (6) 6
medical and health sciences (6) 6
medicin och hälsovetenskap (6) 6
melanoma (6) 6
metastases (6) 6
nivolumab (6) 6
perfusion (6) 6
prognosis (6) 6
renal cell cancer (6) 6
solid tumors (6) 6
targeted therapy (6) 6
taxoids - pharmacokinetics (6) 6
toxicity (6) 6
cancer research (5) 5
cardiology (5) 5
cell biology (5) 5
indoles - adverse effects (5) 5
kinetics (5) 5
medicine & public health (5) 5
neoplasm staging (5) 5
neoplasms - diagnostic imaging (5) 5
neoplasms - drug therapy (5) 5
pharmacology (5) 5
positron-emission tomography - methods (5) 5
pyrroles - adverse effects (5) 5
radiology, nuclear medicine & medical imaging (5) 5
reproducibility of results (5) 5
tomography (5) 5
angiogenesis (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
bevacizumab (4) 4
biomarkers (4) 4
breast-cancer (4) 4
cancer therapies (4) 4
carcinoma, renal cell - pathology (4) 4
clinical medicine (4) 4
disease progression (4) 4
disease-free survival (4) 4
endothelial growth-factor (4) 4
health aspects (4) 4
imaging / radiology (4) 4
immunotherapy (4) 4
klinisk medicin (4) 4
lung neoplasms - diagnostic imaging (4) 4
neoplasm metastasis (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
nuclear medicine (4) 4
oncology, experimental (4) 4
pet/ct scanner (4) 4
pharmacokinetics (4) 4
progression-free survival (4) 4
radiologi och bildbehandling (4) 4
radiology, nuclear medicine and medical imaging (4) 4
risk factors (4) 4
tomography, x-ray computed (4) 4
umcg approved (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


FRONTIERS IN BIOSCIENCE-LANDMARK, ISSN 1093-9946, 01/2009, Volume 14, pp. 2248 - 2268
Journal Article
Cancer Cell, ISSN 1535-6108, 01/2012, Volume 21, Issue 1, pp. 82 - 91
Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs,... 
CELL LUNG-CANCER | POSITRON-EMISSION-TOMOGRAPHY | PET/CT SCANNER | ONCOLOGY | BEVACIZUMAB | VASCULATURE | HYPERTENSION | DOCETAXEL | MYOCARDIAL BLOOD-FLOW | CAPILLARY RECRUITMENT | BREAST | CELL BIOLOGY | Lung Neoplasms - drug therapy | Humans | Middle Aged | Male | Metabolic Clearance Rate | Antineoplastic Agents - therapeutic use | Positron-Emission Tomography | Antineoplastic Agents - administration & dosage | Bevacizumab | Taxoids - therapeutic use | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacology | Bone Marrow - metabolism | Angiogenesis Inhibitors - therapeutic use | Female | Antineoplastic Agents - pharmacokinetics | Thyroid Gland - drug effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Vascular Endothelial Growth Factor A - blood | Angiogenesis Inhibitors - pharmacology | Antineoplastic Combined Chemotherapy Protocols | Taxoids - pharmacokinetics | Taxoids - administration & dosage | Neovascularization, Pathologic - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Thyroid Gland - metabolism | Drugs | Grasslands | Chemotherapy | Drug delivery systems | PET imaging | Oncology, Experimental | Dosage and administration | Research | Drug therapy, Combination | Lung cancer, Non-small cell | Vehicles | Cancer | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63705
Objectives: Pemetrexed is a thymidylate synthase (TS) inhibitor and is effective in non-small cell lung cancer (NSCLC). 3'-deoxy-3'-[F-18] fluorothymidine... 
5-FLUOROURACIL | POLYMORPHISMS | PHARMACOLOGY | MULTIDISCIPLINARY SCIENCES | VALIDATION | PHASE-II | PROLIFERATION | MULTITARGETED ANTIFOLATE | TUMORS | CHEMOTHERAPY | PET | Prognosis | Outcome Assessment (Health Care) | Guanine - analogs & derivatives | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | Methylenetetrahydrofolate Reductase (NADPH2) - metabolism | Positron-Emission Tomography | Antimetabolites, Antineoplastic - administration & dosage | Tissue Distribution | Neoplasm Metastasis | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Time Factors | Guanine - pharmacology | Adult | Antimetabolites, Antineoplastic - pharmacology | Female | Carcinoma, Non-Small-Cell Lung - pathology | Deoxyuridine - blood | Carcinoma, Non-Small-Cell Lung - metabolism | Thymidylate Synthase - metabolism | Pemetrexed | Thymidylate Synthase - genetics | Polymorphism, Genetic | Dideoxynucleosides - pharmacokinetics | Deoxyuridine - metabolism | Glutamates - pharmacology | Glutamates - administration & dosage | Lung Neoplasms - diagnostic imaging | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Thymidylate Synthase - antagonists & inhibitors | Guanine - administration & dosage | Antimitotic agents | PET imaging | Oncology, Experimental | Lung cancer, Small cell | Research | Metastasis | Lung cancer, Non-small cell | Antineoplastic agents | Cancer | Plasma | Nuclear medicine | Emission analysis | Lung cancer | Oncology | Cancer therapies | Metastases | Bone marrow | Tomography | Dihydrofolate reductase | Inhibition | Deoxyribonucleic acid--DNA | Enzymes | Medical imaging | Positron emission | Non-small cell lung carcinoma | Breast cancer | Thymidylate synthase | Patients | Emissions | Solid tumors | Positron emission tomography | Tumors | Deoxyribonucleic acid | DNA
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2013, Volume 19, Issue 1, pp. 183 - 193
Journal Article
Journal Article